Skip to main content
Zealand Pharma logo

Zealand Pharma — Investor Relations & Filings

Ticker · ZEAL ISIN · DK0060257814 LEI · 549300ITBB1ULBL4CZ12 CO Professional, scientific and technical activities
Open in API
Filings indexed 1,529 across all filing types
Latest filing 2024-03-08 Director's Dealing
Country DK Denmark
Listing CO ZEAL

About Zealand Pharma

https://www.zealandpharma.com/

Zealand Pharma is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines. The company's primary focus is on advancing treatments for obesity and metabolic diseases, with a strategic goal to become a leader in this field. Its pipeline includes multiple candidates targeting obesity, such as petrelintide (a long-acting amylin analog) and survodutide (a glucagon/GLP-1 dual agonist licensed to a partner). Beyond metabolic health, Zealand Pharma develops therapies for rare diseases, including dasiglucagon for congenital hyperinsulinism and glepaglutide for short bowel syndrome. The company also has programs in chronic inflammation. Leveraging its expertise in peptide science, the company aims to create next-generation therapeutics to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing Classification · 100% confidence The document follows the standard regulatory template for the notification of transactions by persons discharging managerial responsibilities (PDMRs). It explicitly identifies the individual (Anneline Nansen, a member of the Board of Directors), the nature of the transaction (Sale of Shares), the price, volume, and the date of the transaction. This is a classic 'Director's Dealing' disclosure.
2024-03-08 English
Director's Dealing 2024
Director's Dealing Classification · 100% confidence The document title explicitly mentions 'Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons'. This directly corresponds to insider trading reports or director's dealings. The filing type definition for Director's Dealing is 'DIRS'. Although the document states 'Please see the attached file(s)' and the length is short (2620 chars), suggesting it might be an announcement (RPA/RNS), the specific nature of the content (managerial transactions) strongly points to the dedicated 'DIRS' category over the general 'RPA' or 'RNS' fallback, as 'DIRS' is a more precise classification for this specific regulatory event.
2024-03-05 English
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing Classification · 100% confidence The document contains multiple 'Notification and public disclosure of transactions by persons discharging managerial responsibilities' (PDMR) forms. These forms detail share transactions (exercise of warrants and sale of shares) by company executives and board members (Adam Steensberg, Frederik Barfoed Beck, and Jens Peter Stenvang). This is a standard regulatory requirement for reporting insider dealings, which falls under the 'Director's Dealing' category.
2024-03-05 English
Share Issue/Capital Change 2024
Share Issue/Capital Change Classification · 99% confidence The document is a company announcement titled "Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants." It details the issuance of new shares due to the exercise of employee warrants, the resulting increase in share capital (DKK 102,581 divided into 102,581 new shares), and the total proceeds received. This action directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition of 'Share Issue/Capital Change' (Code: SHA). It is not a general earnings release (ER), a full annual report (10-K), or a simple dividend notice (DIV).
2024-03-05 English
Earnings Release 2023
Earnings Release Classification · 96% confidence The document is titled "Zealand Pharma Announces Financial Results for the Full Year 2023" and contains detailed Key financial results for FY 2023, including a table comparing DKK million figures for FY 2023 and FY 2022, and provides Financial guidance for 2024. It explicitly states it 'today announced the annual report for the year ended December 31, 2023, and provided a corporate update.' While it discusses the annual report, the document itself is a press release summarizing the results and providing an update, which aligns best with an Earnings Release (ER) or potentially a Management Report (MDA) if it were more narrative. However, since it focuses heavily on the key financial figures and guidance for the full year, it functions as the primary announcement of those results. Given the structure—a press release announcing the full-year financial performance—it fits the definition of an Earnings Release (ER) better than the comprehensive 10-K itself, especially since it also mentions a conference call to discuss the results. It is not a short announcement pointing to a separate report (RPA/RNS), as it contains the core financial data. FY 2023
2024-02-27 English
Annual Report (ESEF) 2023
Annual Report (ESEF) Classification · 100% confidence FY 2023
2024-02-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.